GRI

Business Context and Reporting Period

Company: GRI Bio, Inc. (GRI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: GRI is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T cells for idiopathic pulmonary fibrosis (IPF). On June 18, 2026, the FDA granted Orphan Drug Designation to GRI-0621 for IPF. The company also maintains a pipeline including GRI-0803 for autoimmune disorders.

Key Financial Metrics

Note: All share and per-share data reflect reverse stock splits effected in February 2025 and January 2026.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately $2.3 million (39%) compared to the prior six-month period. Research and Development (R&D) expenses dropped significantly from $3.5 million to $0.8 million, primarily due to the completion of the Phase 2a clinical trial for GRI-0621.
• Financing Activity: The company raised approximately $8.2 million in gross proceeds through its At-The-Market (ATM) offering during the six months ended June 30, 2026. This contrasts with the prior period, which included a $5.0 million public offering in April 2025.
• Liquidity Improvement: Cash and cash equivalents increased by $2.7 million to $10.9 million, driven by financing proceeds offsetting operating cash burn.
• Share Count: Outstanding shares increased from approximately 498,000 at year-end 2025 to 2,186,115 as of June 30, 2026, due to ATM sales and warrant exercises.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management states there is "substantial doubt" about the company's ability to continue as a going concern for one year from the filing date. Current cash is projected to fund operations through the second quarter of 2027, but only if the company limits activities to preliminary work for additional clinical studies. Completing full clinical trials requires substantial additional capital.
• Nasdaq Listing Risk: The company's Market Value of Listed Securities (MVLS) is below $5 million. A new Nasdaq requirement (currently stayed by the SEC) would mandate a $5 million MVLS. If effective, failure to comply could lead to immediate suspension of trading and delisting, severely impairing capital raising ability.
• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to accounting software limitations and insufficient segregation of duties. Management has implemented compensating controls but notes they must operate for a sufficient period to be considered remediated.
• Outlook: The company intends to request an FDA meeting regarding a proposed Phase 2b/3 adaptive trial design for GRI-0621. Development of GRI-0803 is paused pending additional funding, with plans to file an IND in the first half of 2027 if resources allow.

Investor Verification Checklist

• Cash Runway: Verify the specific assumptions regarding the "preliminary work" limitation required to extend cash to Q2 2027.
• Capital Raising: Monitor the status of the stayed Nasdaq MVLS requirement and the company's ability to access the ATM facility if delisting risks materialize.
• Clinical Progress: Confirm the timeline and capital requirements for the proposed Phase 2b/3 trial for GRI-0621 following FDA feedback.
• Internal Controls: Review future filings to confirm the remediation of the material weakness in internal controls over financial reporting.
• Dilution: Assess the impact of outstanding warrants (approx. 517,000 shares) and options (15,032 shares) on future share count and per-share value.